GlassScriptPhysician profile
Ronald Patterson
NPI 1376159400
$24,527.60
in general payments reported to CMS, 2019-2025
25 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $6,418 · 2023: $13K · 2024: $2,510 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,763 · Food and Beverage: $6,911 · Travel and Lodging: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,762.50 |
| Food and Beverage | $6,911.09 |
| Travel and Lodging | $1,114.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,100.78 | 2021-2025 | |
| Alkermes, INC. | $881.66 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $852.91 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $846.88 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $715.49 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $401.40 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $317.69 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $284.70 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $271.69 | 2022-2025 | Caplyta |
| Tris Pharma INC | $232.09 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $216.24 | 2022-2024 | Quviviq |
| Corium, LLC | $211.05 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $183.32 | 2023-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $171.08 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $150.48 | 2022-2025 | Ingrezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $141.92 | 2022-2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $120.36 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $114.55 | 2022-2025 | Austedo Xr, Uzedy |
| Merck Sharp & Dohme LLC | $78.97 | 2021-2023 | Belsomra |
| Bausch Health US, LLC | $69.34 | 2022-2024 | Aplenzin |
| Janssen Pharmaceuticals, INC | $44.65 | 2022-2025 | Spravato |
| Noven Therapeutics, LLC | $44.42 | 2023-2025 | Xelstrym, Secuado |
| Tms Neurohealth Centers INC. | $33.49 | 2025 | Tms Neurohealth Centers INC. |
| E.R. Squibb & Sons, L.L.C. | $30.96 | 2025 | Cobenfy |
| Aytu Biopharma, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.